170011-47-9

Basic information

• Product Name: 1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate
• Synonyms: 1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate
• CAS NO: 170011-47-9
• Molecular Formula: C₉H₁₁F₃O₅S
• Molecular Weight: 288.241
• Mol File: 170011-47-9.mol

Chemical Properties

• Boiling Point: 339.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.53±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate(170011-47-9)
• EPA Substance Registry System: 1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate(170011-47-9)

Safety Data

• Hazardous Substances Data: 170011-47-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate is used as a reagent for the synthesis of various pharmaceutical compounds. Its ability to form carbon-carbon and carbon-heteroatom bonds is crucial for the creation of complex molecular structures that are often found in modern medications.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, 1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate serves as a reagent in the synthesis of compounds used in agricultural chemicals. Its role in bond formation is essential for developing new pesticides, herbicides, and other agrochemical products that require specific molecular configurations for effectiveness.
Used as a Lewis Acid Catalyst:
1,4-dioxaspiro[4.5]dec-7-en-8-yl trifluoromethanesulfonate is also utilized as a Lewis acid catalyst in a variety of organic reactions. Its catalytic properties are employed to accelerate reaction rates and improve the yield of desired products, making it an indispensable tool in both academic and industrial organic chemistry research and development.

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 456-64-4 phenyl trifluoromethanesulfonamide 
• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 145100-50-1 1,1,1-trifluoro-N-(pyridin-2-yl)-N-((trifluoromethyl)sulfonyl)methane sulfonamide 
• 145100-51-2 N-(5-chloropyridin-2-yl)-1,1,1-trifluoro-N-[(trifluoromethyl)sulphonyl]methanesulphonamide 

Downstream Products

• 122770-40-5 8-(4-Fluorophenyl)-1,4-dioxaspiro[4.5]dec-7-ene 
• 680596-79-6 4,4,5,5-tetramethyl-2-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-1,3,2-dioxaborolane 
• 1128268-54-1 Methyl 4-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)-2-methylbenzoate 
• 1128268-43-8 Ethyl 4-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)benzoate 
• 87014-19-5 (3aR,7aR)-3a-(3,4-Dimethoxy-phenyl)-hexahydro-benzofuran-2,6-dione 

Relevant articles and documents

Optimization of Phenyl Indole Inhibitors of the AAA+ ATPase p97

Optimization of the side-chain of a phenyl indole scaffold identified from a high-throughput screening campaign for inhibitors of the AAA+ ATPase p97 is reported. The addition of an N-alkyl piperazine led to high potency of this series in a biochemical assay, activity in cell-based assays, and excellent pharmaceutical properties. Molecular modeling based on a subsequently obtained cryo-EM structure of p97 in complex with a phenyl indole was used to rationalize the potency of these allosteric inhibitors.

Stille/diels-alder reaction sequences: Diversity-oriented access to novel steroids

An efficient, diversity-oriented approach to novel steroid analogues possessing a C-5β configuration begins with the Stille cross-coupling of enantiomerically pure cycloalkenylstannane trans-2 and enol triflate 3. The resulting diene trans-4 engages in Di

Discovery of highly potent heme-displacing IDO1 inhibitors based on a spirofused bicyclic scaffold

Through structural modification of an oxalamide derived chemotype, a novel class of highly potent, orally bioavailable IDO1-specific inhibitors was identified. Representative compound 18 inhibited human IDO1 with IC50 values of 3.9 nM and 52 nM in a cellular and human whole blood assay, respectively. In vitro assessment of the ADME properties of 18 demonstrated very high metabolic stability. Pharmacokinetic profiling in mice showed a significantly reduced clearance compared to the oxalamides. In a mouse pharmacodynamic model 18 nearly completely suppressed lipopolysaccharide-induced kynurenine production. Hepatocyte data of 18 suggest the human clearance to be in a similar range to linrodostat (1).

A Straightforward Synthesis of Trideuterated α-Terpinene for Mechanistic Studies

Regiospecifically trideuterated (2,6,6-2H3)-α-terpinene was prepared in six steps and with a deuterium incorporation of >99 % in 24 % yield from 1,4-cyclohexanedione monoethylene ketal. The synthetic procedure involved twofold cross-coupling reactions of alkylcuprates (lithium dimethylcuprate and chloromagnesium cyano(isopropyl)cuprate, respectively) with enol triflates to introduce the alkyl substituents on the 1,3-cyclohexadiene backbone. By changing the alkylcuprates, the synthetic approach could serve as a prototype for the synthesis of various 1,4-dialkyl-substituted 1,3-cyclohexadiene derivatives, which could be deuterium-labeled as well, for example for mechanistic studies.

Stereocontrolled synthesis of the cis-hydroxydecalin system: Towards biologically active 19-nor-clerodanes

The 19-nor-clerodanes are compact, densely functionalized diterpenes based on a stereocentre-rich decalin scaffold. To date only a few examples of the 19-nor-clerodanes have been synthesized, hence new flexible strategies are required. We herein describe the stereocontrolled construction of the cis-hydroxy decalin core in a concise fashion.

Development of a Stereoselective and Scalable Synthesis for the Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor, BMT-297376; N-((R)-1-((cis)-4-(3-(Difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl)propyl)-6-methoxynicotinamide

The current work describes a stereoselective and scalable route to N-((R)-1-((cis)-4-(3-(difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl)propyl)-6-methoxynicotinamide (1) from readily available 1,4-dioxaspiro[4.5]decan-8-one. The developed process encompasses an efficient 1,4-trans-selective synthesis of (trans)-4-(3-(difluoromethyl)-2-methoxypyridin-4-yl)cyclohexyl methanesulfonate as the key intermediate and the use of Ellman sulfinamine methodology to install an alkyl amine in a stereoselective manner. Various synthetic routes were screened to accomplish a stereoselective and scalable protocol to access the title compound (1). This advancement enabled a competent route to the title compound in an enantioselective, safe, cost-effective, and scalable manner.

Total synthesis of the Kopsia lapidilecta alkaloid (±)-lapidilectine B

The total synthesis of Kopsia lapidilecta alkaloid (±)-lapidilectine B is described. Notable elements of this synthesis include the first natural products application of the Smalley azido-enolate cyclization to form the 1,2-dihydro-3H-indol-3-one (indoxyl

BICYCLOHEPTANE PYRROLIDINE OREXIN RECEPTOR AGONISTS

The present invention is directed to bicyclo[4.1.0]heptane pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

3-OXAZOLINONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF

The present invention relates to a novel 3-indazolinone compound that regulates or inhibits the activity of indoleamine 2,3-dioxygenase (IDO), the method for the preparation thereof and the use thereof in medicine. In particular, the present invention relates to a compound represented by the general formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof, a method for treating or preventing IDO-mediated diseases, especially tumors, by use of the compound or a pharmaceutically acceptable salt thereof, and a method for preparing the compound or a pharmaceutically acceptable salt thereof. The present invention further relates to use of the compound or a pharmaceutically acceptable salt thereof or a composition comprising the compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing IDO-mediated diseases, especially tumors.Wherein the substituents of the general formula (I) are defined the same as that in the specification.

Arylamine compound, pharmaceutical composition containing arylamine compound as well as preparation method and application of arylamine compound

The present invention relates to an arylamine compound of a formula (I), a pharmaceutical composition comprising the same, a preparation method of the arylamine compound and application of the pharmaceutical composition in the prevention or treatment of diseases or conditions associated with RET activity.